Abstract
Introduction: Although the therapeutic effects of probiotics in atopic dermatitis (AD) are known, the limited findings in adults are inconsistent. Lactobacillus plantarum (LP) IS-10506 was found to improve AD symptoms due to its immunomodulatory effects. Objective: To assess the Scoring Atopic Dermatitis Index (SCORAD), the serum immunoglobulin E (IgE), interleukin (IL)-4, interferon-gamma (IFN-γ), forkhead box P3 (Foxp3+), and IL-17 levels in adults with mild and moderate AD after LP IS-10506 supplementation. Methods: A randomized double-blind placebo-controlled trial comparing the microencapsulated probiotic (2 × 1010 CFU/day) and placebo (skim milk-Avicel) was conducted at an outpatient clinic on 30 adults with mild and moderate AD. The patients were divided into 2 groups with 15 patients each: intervention and control. Result: The SCORAD score was significantly lower in the probiotic than the placebo group on the 8th week. The IL-4 and IL-17 levels were significantly lower in the probiotic than the placebo group. The IFN-γ and Foxp3+ levels were significantly higher in the probiotic than the placebo group. However, the IgE levels remained significantly unchanged. Conclusion: The administration of LP IS-10506 is effective for alleviating AD symptoms in adults owing to its immunomodulatory effects.
Original language | English |
---|---|
Pages (from-to) | 1491-1498 |
Number of pages | 8 |
Journal | Journal of Dermatological Treatment |
Volume | 33 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- Atopic dermatitis
- Lactobacillus plantarum
- adult
- probiotic